A new study led by the University of Bristol has shown a common eye condition, glaucoma, could be successfully treated with a single injection using gene therapy, which would improve treatment options, effectiveness and quality of life for many patients.
Glaucoma affects over 64 million people worldwide and is a leading cause of irreversible blindness. It is usually caused by fluid building up in the front part of the eye, which increases pressure inside the eye and progressively damages the nerves responsible for sight. Current treatments include either eye drops, laser or surgery, all of which have limitations and disadvantages.
The research team led by academics at the Bristol Medical School: Translational Health Sciences tested a new approach that could provide additional treatment options and benefits. Their findings are published in the journal Molecular Therapy.
The researchers designed a gene therapy and demonstrated proof of concept using experimental mouse models of glaucoma and human donor tissue.
The treatment targeted part of the eye called the ciliary body, which produces the fluid that maintains pressure within the eye. Using the latest gene editing technology called CRISPR, a gene called Aquaporin 1 in the ciliary body was inactivated leading to reduced eye pressure.
Dr Colin Chu, Visiting Senior Research Fellow in the Bristol Medical School: Translational Health Sciences and corresponding author, said: “Currently there is no cure for glaucoma, which can lead to loss of vision if the disease is not diagnosed and treated early.
“We hope to advance towards clinical trials for this new treatment in the near future. If it’s successful it could allow a long-term treatment of glaucoma with a single eye injection, which would improve the quality of life for many patients whilst saving the NHS time and money.”
The academics are currently in discussion with industry partners to support further laboratory work and rapidly progress this new treatment option towards clinical trials.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Eye Center South welcomes glaucoma specialist Dr. Ronald P. Swendrison October 2, 2020 at 12:58 pm
Dr. Swendris then completed his Glaucoma Fellowship at Kresge Eye Institute at Wayne State University in Detroit, MI in 1991. In addition to serving as Assistant Clinical Professor at the Wayne ...
- In the future glaucoma eye tests could be performed at homeon September 30, 2020 at 8:01 am
Glaucoma is a chronic condition that affects cells at the back of the eye. It is the leading cause of irreversible blindness worldwide, and is responsible for 1 in 10 cases of serious sight impairment ...
- Glaucoma can lead to vision loss but often goes unnoticed until it’s too lateon September 29, 2020 at 2:44 pm
However, for the 70 million people worldwide living with glaucoma, they risk going blind if they can’t get to a doctor’s office for routine procedures and visits. Glaucoma is one of the primary causes ...
- Europe Glaucoma Market and Competitive Landscape Report 2020: Pipeline, Epidemiology, Market Valuations, Drug Sales, Market Forecast, Drug Forecasts, and Market Shares 2016 ...on September 28, 2020 at 8:25 am
The "Europe Glaucoma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering. The research report Europe Glaucoma Market and Competitive Landscape - 2020, ...
- Comparisons of glaucoma surgeries show certain techniques are safer, more effectiveon September 28, 2020 at 4:36 am
Two recent studies by a UB researcher could help increase safety and minimize expense for patients undergoing glaucoma surgery. The studies were conducted over several years by Asher Weiner, clinical ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Glaucoma gene therapy
- How gene therapy is offering new hopeon October 6, 2020 at 10:28 pm
As we get set to celebrate World Sight Day 2020, our new video explains the potential of gene and cell therapy to stall vision loss and ...
- Gene therapy research gives hope on World Sight Dayon October 5, 2020 at 4:38 am
Nicole and Kate Barrett with guide dog Misty. The potential of gene therapy to prevent blindness and restore sight for eye diseases that have long ...
- Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosaon October 5, 2020 at 4:04 am
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announced the U.S. Food and Drug Administration (FDA) has granted ...
- 23 Medical Uses Of Marijuanaon October 4, 2020 at 10:35 pm
Marijuana use can be used to treat and prevent the eye disease glaucoma, which increases pressure ... Cannabidiol stops cancer by turning off a gene called Id-1, the study, published in the ...
- Challenges in Neuroprotective Nanomedicine Development: Progress Towards Noninvasive Gene Therapy of Glaucomaon October 3, 2020 at 5:00 pm
Gene therapy for glaucoma is a treatment that aims to stop and reverse vision loss in glaucoma patients by promoting cellular mechanisms associated with RGC protection and suppressing those ...